|
Continued from first page.....
In some strains of mice, fed high levels of 22:6w3, host resisitance to infectious organisms such as Listeria monocytogenes may be affected. This appears to be related to reduced expression of the major histocompatibility complex class II antigen via down-regulation of the interferon-receptor (Fritsche et al., 1996, Fritsche and Feng, 1997).
That increased unsaturation of fatty acyl groups in membrane phospholipids is associated with significant changes in function is not be surprising. Cold acclimation in poikilotherms has long been liked to their ability to compensate by increasing the unsaturation of cellular membrane phospholipids in order to maintain membrane permeability and fluidity, and to modulate the activity of membrane-bound enzymes (Selivonchick et al., 1977). Loss of this adaptive response plus the diversion from the diet of our pre-industrial era ancestors may underlie our poor w3 fatty acid status. Perhaps we should reflect upon the medical philosophy of Hippocrate, a system based on nature's processes in the management of disease. This may well include our return to the higher w3 fatty acid diet. Nature provides us with a wide range of foods, both animal and vegetable, rich in nutrients known to be essential including the fatty acids and many vitamins and minerals. They have been available for centuries. We simply have to take the time and effort to exploit this diversity.
Regarding future research it is clear that we are increasingly recognizing the importance of the fact that the body acts in concert. The brain-body connection is recognized in the relatively new discipline of neuroimmunology. Further investigation of the holistic approach is indicated.
Patricia V. Johnston PhD
University of Illinois at Urbana Champaign
Dept. of Human Nutrition
382D Ag. Ang. Sci. Build
1304 West Pennsylvania Ave
Urbana, IL 61801
References
Ferber, E. and Resch, K. (1977) In: "Lymphocyte Structure and Function" (J. J. Marchalonis ed.) pp. 593-621 Dekkor, New York.
Fritsche, K.L. and Johnston, P.V. (1989) Lipids, 24:305.
Fritsche, K.L. and Johnston, P.V. (1990) J. Nutr. 120:1601.
Fritsche, K.L., Shagbazian, L.M., Feng, C., and Berg, J.N. (1996) Clin. Sci. 92:?.
Fritsche, K.L. and Feng, C. (1977) J. Interferon & Cytokine Res. (in press).
Gurr, M.I. (1983) Prog. Lipid, Res. 22:257.
Holman R.J., Johnson, S.B. and Hatch, T.F. (1982) Am. J. Clin. Nutr. 35:617.
Jenski, L.J., Sturdevant, L.K., Ehringer, W.P. and Stilllwell, W. (1991) Lipids, 26:353.
Jenski, L.J., Bowber, G.M., Johnson, M.A., Ehringer, W.D., Fetterhoff, T., and Stillwell, W. (1995) Biochim. Biophys. Acta. 1236:39.
Johnston, P.V. (1985) Adv. Lipid Res. 21:103-141.
Johnston, P.V. (1988) In: "Contemporary Issues in Clinical Nutrition" Nutrition and Immunology (R. K. Chandra ed. ) Alan R. Liss Inc., New York, Vol 11:37.
Meade, G. J. and Mertin, J. (1978) Adv. Lipid Res. 16:127-165.
Pascale, A.W., Ehringer, W. D., Stillwell, W., Sturdevant, L.K. and Jenski, L.J. (1993) Nutr. Cancer, 19:147.
Selivonchick, D. P. and Johnston, P. V. (1975) J. Nutr. 10 5:288.
Selivonchick, D.p., Johnston, P. V. and Roots, B. I. (1977) Neuro Chem. Res. 2:379.
Zerouga, M., Stillwell, W., Stone, J., Powner, A. and Jenski, L.J. (1996) Anticancer Res. 16:2863.
|